NCT04345276View on ClinicalTrials.gov

Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 18, 2020

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions
COVID-19
Interventions
DRUG

Danoprevir+Ritonavir

Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.

Trial Locations (1)

430104

Huoshenshan Hostipal, Wuhan

Sponsors
All Listed Sponsors
collaborator

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

lead

Huoshenshan Hospital

OTHER

NCT04345276 - Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter